Sun Pharma Licenses Lerodalcibep from LIB Therapeutics for All Markets Outside US and China
核心洞察
Sun Pharmaceutical Industries and LIB Therapeutics (搜索) signed an exclusive global licensing, commercialization and manufacturing agreement for the once-monthly PCSK9 inhibitor lerodalcibep, covering all markets except the United States and China.
Lerodalcibep won European Commission marketing authorization on September 21, 2026 as Lyrokaul for adult hypercholesterolaemia (搜索) and mixed dyslipidaemia (搜索), and is FDA-approved in the US as Lerochol.
The licensed territories represent a PCSK9 inhibitor market valued at US$3.7 billion in MAT Q2 2026 and growing at 38% CAGR, with Europe alone accounting for US$2.9 billion.
Sun Pharmaceutical Industries Limited and LIB Therapeutics (搜索) Inc. announced on September 28, 2026 an exclusive licensing, commercialization and manufacturing agreement for lerodalcibep, a once-monthly PCSK9 inhibitor for LDL-cholesterol lowering. Under the deal, Sun Pharma holds worldwide rights to commercialize and manufacture the therapy in all markets excluding the United States and China, with a limited number of other excluded territories to be covered through separate agreements between the two companies.
The European Commission granted marketing authorization for lerodalcibep on September 21, 2026, where it is sold as Lyrokaul for the treatment of adult patients with hypercholesterolaemia (搜索) and mixed dyslipidaemia (搜索). In the United States, the FDA has approved the drug as Lerochol (lerodalcibep-liga) as an adjunct to diet and exercise to reduce LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (搜索) (HeFH). Sun Pharma will be responsible for pursuing regulatory approvals in licensed territories where approval has not yet been obtained.
Deal Terms and Market Access
LIB will receive an upfront payment and future milestone payments, together with royalties based on net sales in the licensed territories. Other terms of the agreement are confidential.
According to IQVIA, the PCSK9 inhibitor market outside the United States and China reached US$3.7 billion in the period ending Q2 2026 (MAT Q2 2026), growing at 38% CAGR over the preceding two years. Europe alone accounted for US$2.9 billion of that market in MAT Q2 2026. The global PCSK9 inhibitor market is approaching US$7 billion in 2026.
"Once-monthly lerodalcibep dosing, with robust LDL-C reduction and the added benefits of a small-volume injection and six-month ambient storage, simplifies treatment for patients and offers greater convenience," said Kirti W Ganorkar, Managing Director of Sun Pharma. "This agreement marks a significant step in strengthening our global innovative medicines portfolio, particularly in cardiovascular care. With exclusive rights outside the United States and China, we look forward to expanding access to this important treatment option for patients globally."
Unmet Need in LDL-C Control
The companies framed the agreement around a persistent gap between guideline targets and real-world lipid control. Many patients at high or very high cardiovascular risk remain above recently updated and more globally harmonized 2026 guideline-recommended LDL-C goals despite treatment. In the DA VINCI observational study across 18 European countries, only 33% of patients assessed on stable oral lipid-lowering therapy achieved their risk-based 2019 European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) LDL-C goals. Those 2019 goals were applied retrospectively to data collected in 2017-2018, and the 33% figure relates to patients assessed on stable therapy.
Treatment guidelines now emphasize both additional LDL-C reductions and lower targets for patients with, or at very high or high, cardiovascular disease risk, with additional therapies when statins alone are insufficient. PCSK9 inhibitors provide the efficacy and safety to achieve these goals, according to the companies.
"LIB is extremely pleased to partner with Sun Pharma, a well-established global pharmaceutical company with a growing focus on innovative medicines," said Evan Stein, MD, PhD, chief operating and scientific officer and co-founder of LIB Therapeutics (搜索). "Sun Pharma's international presence and experience in building global innovative brands make it an ideal partner to bring lerodalcibep to more patients. Together, we aim to expand access for patients with cardiovascular disease, or at high cardiovascular risk, who need substantial additional LDL-cholesterol reductions despite existing treatment."
Product Profile and Phase 3 Data
Lerochol is described as a novel antibody-mimetic recombinant-fusion protein PCSK9 inhibitor, and the only PCSK9 inhibitor with a once-monthly, small single-injection dose that patients self-administer, with room temperature storage for up to three months in a recently approved autoinjector device. The EU product carries six-month ambient storage. The FDA recently approved an update to the Lerochol indication statement in its prescribing information reflecting the reduction of risk for major adverse cardiovascular events (MACE) achieved in adults through LDL-C lowering with statins or with monoclonal antibody PCSK9 inhibitors used as an add-on to statin therapy.
FDA approval of Lerochol was based on data from the global Phase 3 LIBerate Clinical Trial Program, which enrolled more than 2,900 patients with cardiovascular disease, without CVD but at very high and high risk for CVD, and including heterozygous and homozygous familial hypercholesterolemia. Lerodalcibep was dosed once monthly for up to 52 weeks in the key registration-enabling, placebo-controlled trials, and more than 2,400 patients continued into a 72-week open-label extension trial.
In clinical trials, Lerochol demonstrated sustained LDL-C reductions of at least 60% in patients with, or at very high or high risk of, cardiovascular disease, and at least 59% in those with HeFH who have more severe LDL-C elevations. The therapy was generally well tolerated across the LIBerate program, with no treatment-related serious adverse events reported in the long-term extension studies.
Commercial Rollout
In the United States, LIB plans to make the Lerochol autoinjector available by January 2027. Insurance coverage is expected to expand gradually over the course of 2027, and when launched, the autoinjector will sit alongside the pre-filled syringe in the company's direct-to-patient cash pay program at $199 per month.
In Greater China, a Biologics License Application for lerodalcibep has been submitted by LIB's licensing partner Everest Medicines (搜索), with potential approval in 2027. The excluded China territory comprises mainland China, Hong Kong, Macau and Taiwan.
Sun Pharma's Global Innovative Medicines portfolio spans dermatology, ophthalmology and onco-dermatology and accounts for about 22% of company sales. The company operates in more than 100 countries.